Rhumbline Advisers Puma Biotechnology, Inc. Transaction History
Rhumbline Advisers
- $121 Billion
- Q3 2025
A detailed history of Rhumbline Advisers transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 60,001 shares of PBYI stock, worth $297,004. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,001
Previous 60,611
1.01%
Holding current value
$297,004
Previous $207,000
48.31%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.1MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...